| NCT06842498 | A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Recruiting | Feb 22, 2026 | Mar 31, 2028 (estimated) |
| NCT07722988 | A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS) | Phase 3 | Not yet recruiting | 2027-04 | 2030-09 (estimated) |
| NCT03941093 | Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer | Phase 3 | Completed | May 10, 2019 | Jun 11, 2024 (actual) |
| NCT03955146 | Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Phase 3 | Terminated | Jun 18, 2019 | Mar 20, 2023 (actual) |
| NCT02606136 | Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | Phase 2 | Terminated | Jan 4, 2016 | May 7, 2020 (actual) |
| NCT04632940 | Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD | 3 | Terminated | Mar 3, 2021 | Jun 12, 2023 (actual) |
| NCT04419558 | Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Phase 3 | Terminated | Sep 30, 2020 | Sep 4, 2023 (actual) |
| NCT03263091 | Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden | Phase 3 | Terminated | Jan 29, 2018 | Mar 9, 2023 (actual) |
| NCT04371666 | Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD) | 3 | Terminated | Aug 10, 2020 | Feb 13, 2023 (actual) |
| NCT00074698 | Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Dec 8, 2003 | Not listed |
| NCT05301517 | A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies | Phase 3 | Completed | Mar 16, 2022 | Apr 3, 2023 (actual) |
| NCT03303066 | Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS) | Phase 2/Phase 3 | Completed | Jun 6, 2018 | Jan 11, 2023 (actual) |
| NCT02210559 | A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer | Phase 1/Phase 2 | Completed | Jul 31, 2014 | Dec 15, 2021 (actual) |
| NCT04410198 | Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants | Phase 3 | Completed | May 26, 2020 | Jun 30, 2021 (actual) |
| NCT04484857 | Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants | Phase 3 | Completed | Jul 22, 2020 | Jul 9, 2021 (actual) |
| NCT04432298 | Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease | Phase 2 | Terminated | Jun 20, 2020 | Mar 22, 2021 (actual) |
| NCT04621331 | Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD | Phase 3 | Withdrawn | May 23, 2022 | May 23, 2022 (actual) |
| NCT04076943 | Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia | Phase 2 | Completed | Aug 20, 2019 | Mar 26, 2021 (actual) |
| NCT04059913 | Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease | Phase 4 | Completed | Jun 11, 2019 | Nov 19, 2021 (actual) |
| NCT01244763 | Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia | Phase 2 | Completed | Oct 29, 2010 | Jun 13, 2012 (actual) |
| NCT01147666 | Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis | Phase 2 | Completed | May 17, 2010 | Oct 15, 2012 (actual) |
| NCT00761657 | Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis | 2 | Completed | Nov 1, 2006 | Jun 21, 2010 (actual) |
| NCT02273726 | Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis | Phase 3 | Completed | Jan 15, 2015 | Sep 19, 2018 (actual) |
| NCT01414075 | Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment | Phase 2 | Completed | Jul 21, 2011 | Jan 10, 2013 (actual) |
| NCT01750190 | A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis | Phase 3 | Completed | Nov 5, 2012 | Sep 24, 2018 (actual) |
| NCT01630889 | Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease | Phase 2 | Completed | May 18, 2012 | Dec 12, 2019 (actual) |
| NCT02052310 | Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants | Phase 3 | Completed | Feb 11, 2014 | Sep 21, 2018 (actual) |
| NCT01890265 | Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Completed | Jul 30, 2013 | Nov 16, 2017 (actual) |
| NCT01262001 | Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | 2011-03 | Jun 26, 2014 (actual) |
| NCT00754143 | Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy | 1 | Completed | 2008-03 | 2009-12 (actual) |
| NCT00782561 | Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS) | Phase 1 | Terminated | 2008-04 | Jun 18, 2009 (actual) |
| NCT00913393 | Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy | Phase 2 | Terminated | 2009-02 | 2010-06 (actual) |
| NCT02652819 | FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis | Phase 3 | Completed | 2015-12 | Jan 24, 2017 (actual) |
| NCT02652806 | FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease | Phase 3 | Completed | 2015-12 | Jan 24, 2017 (actual) |
| NCT01217632 | A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection | Phase 2 | Terminated | 2010-08 | 2015-06 (actual) |
| NCT01181245 | A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer | 1 | Completed | 2008-12 | 2014-05 (actual) |
| NCT01599507 | Study of FG-4592 in Subjects With Chronic Kidney Disease in China | Phase 2 | Completed | 2011-12 | 2013-01 (actual) |
| NCT01596855 | Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China | Phase 2 | Completed | 2011-09 | 2013-01 (actual) |
| NCT01376063 | Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects | Phase 1 | Completed | 2010-03 | 2010-05 (actual) |
| NCT00102297 | Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus | Phase 1 | Completed | 2005-01 | Not listed |
| NCT00456053 | A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin | Phase 2 | Completed | 2005-12 | Not listed |
